FimmCyte is focused on developing a novel, non-hormonal treatment for late-stage endometriosis, aiming to provide a disease-modifying solution for this condition. Their approach is based on the discovery of a specific protein that is overexpressed in endometriosis cells compared to normal tissues. This unique characteristic enables targeted elimination of the diseased tissue, potentially leading to more effective treatment outcomes for patients suffering from endometriosis.

The company emphasizes the efficacy of their treatment in both patient samples and animal models, indicating promising results in their research and development efforts. By concentrating on a targeted mechanism that addresses the underlying pathology of endometriosis, FimmCyte aims to accelerate the path toward a cure, distinguishing their approach from traditional hormonal therapies that are currently available.

Switzerland

FimmCyte is a pre-clinical stage company dedicated to developing non-hormonal treatments for endometriosis using the immune system. Their vision is to accelerate the path towards an endometriosis cure.

FimmCyte

Company Details